Literature DB >> 17451374

Natural history of hyperplastic callus formation in osteogenesis imperfecta type V.

Moira S Cheung1, Francis H Glorieux, Frank Rauch.   

Abstract

UNLABELLED: Hyperplastic callus formation was assessed in 23 patients with osteogenesis imperfecta type V. Hyperplastic callus mostly affected long bones in the lower extremities and occurred predominantly during phases of rapid growth.
INTRODUCTION: Hyperplastic callus (HPC) formation is one of the most conspicuous features of osteogenesis imperfecta (OI) type V, but the natural history of HPC has not been well characterized.
MATERIALS AND METHODS: In this retrospective single-center study, we assessed HPC in 23 OI type V patients (9 females and 14 males).
RESULTS: Fifteen patients (65%) had HPC at 48 skeletal sites, 30 of which affected the lower limbs. The number of HPC sites per patient ranged from 0 to 7, with an average of 2.6 for men and 1.1 for women (p = 0.047 for this sex difference; t-test). New HPC formation was observed both after fractures and outside of the context of fractures. Only a minority of lower limb fractures (26%) precipitated HPC formation. After an initial enlargement phase, HPC lesions usually stabilized, but could also resolve completely (n = 2) or progress and lead to bone deformation. The most common complication of HPC was a fracture through the lesion (n = 7). Neither pamidronate nor indomethacin seemed to influence the course of HPC.
CONCLUSIONS: HPC is a potentially serious complication of OI type V. Given the rarity of the disorder, treatment studies will require multicenter collaborations.

Entities:  

Mesh:

Year:  2007        PMID: 17451374     DOI: 10.1359/jbmr.070418

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  29 in total

Review 1.  IFITM5 mutations and osteogenesis imperfecta.

Authors:  Nobutaka Hanagata
Journal:  J Bone Miner Metab       Date:  2015-06-02       Impact factor: 2.626

Review 2.  Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.

Authors:  P Trejo; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

Review 3.  Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation.

Authors:  Joan C Marini; Adi Reich; Simone M Smith
Journal:  Curr Opin Pediatr       Date:  2014-08       Impact factor: 2.856

Review 4.  Osteogenesis imperfecta: diagnosis and treatment.

Authors:  A Biggin; C F Munns
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

5.  PHENOTYPIC VARIABILITY IN INDIVIDUALS WITH TYPE V OSTEOGENESIS IMPERFECTA WITH IDENTICAL IFITM5 MUTATIONS.

Authors:  Jamie Fitzgerald; Paul Holden; Hollis Wright; Beth Wilmot; Abigail Hata; Robert D Steiner; Don Basel
Journal:  J Rare Disord       Date:  2013-12

6.  Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression.

Authors:  Adi Reich; Alison S Bae; Aileen M Barnes; Wayne A Cabral; Aleksander Hinek; Jennifer Stimec; Suvimol C Hill; David Chitayat; Joan C Marini
Journal:  J Clin Endocrinol Metab       Date:  2014-11-11       Impact factor: 5.958

Review 7.  New genes in bone development: what's new in osteogenesis imperfecta.

Authors:  Joan C Marini; Angela R Blissett
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

8.  Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.

Authors:  J A Meganck; D L Begun; J D McElderry; A Swick; K M Kozloff; S A Goldstein; M D Morris; J C Marini; M S Caird
Journal:  Bone       Date:  2013-06-14       Impact factor: 4.398

9.  A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor.

Authors:  Charles R Farber; Adi Reich; Aileen M Barnes; Patricia Becerra; Frank Rauch; Wayne A Cabral; Alison Bae; Aaron Quinlan; Francis H Glorieux; Thomas L Clemens; Joan C Marini
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

10.  Clinical and Molecular Characterization of Osteogenesis Imperfecta Type V.

Authors:  Evelise Brizola; Eduardo P Mattos; Jessica Ferrari; Patricia O A Freire; Raquel Germer; Juan C Llerena; Têmis M Félix
Journal:  Mol Syndromol       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.